Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials

References

• de Freitas do Carmo LP, Macedo E. Contrast-induced nephropathy: Attributable incidence and potential harm. Crit Care. 2012;16:127
   PubMedGoogle Scholar
• Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780–1785
   PubMed Web of Science ®Google Scholar
• Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (remedial): A randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211–1217
   PubMed Web of Science ®Google Scholar
• Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
   PubMed Web of Science ®Google Scholar
• Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010;5:4–9
   PubMed Web of Science ®Google Scholar
• Huber W, Eckel F, Hennig M, et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acetylcysteine, theophylline, or both? A randomized study. Radiology. 2006;239:793–804
   PubMedGoogle Scholar
• Feldkamp T, Kribben A. Contrast media induced nephropathy: Definition, incidence, outcome, pathophysiology, risk factors and prevention. Minerva Med. 2008;99:177–196
   PubMedGoogle Scholar
• Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: Cause and effect? Clin J Am Soc Nephrol. 2009;4:1162–1169
   PubMed Web of Science ®Google Scholar
• Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000;2:208–217
   PubMedGoogle Scholar
• Katholi RE, Woods WT Jr, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64–71
   PubMed Web of Science ®Google Scholar
• Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843–849
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279–285
   PubMed Web of Science ®Google Scholar
• Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104:519–524
   PubMedGoogle Scholar
• Yoshida S, Kamihata H, Nakamura S, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 2009;54:192–198
   PubMedGoogle Scholar
• Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63:62–70
   PubMed Web of Science ®Google Scholar
• Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the prato-acs study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63:71–79
   PubMed Web of Science ®Google Scholar
• Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty – contrast-induced nephropathy] trial). Am J Cardiol. 2011;108:1–7
   PubMed Web of Science ®Google Scholar
• Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008–3016
   PubMed Web of Science ®Google Scholar
• Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute st-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012;122:195–202
   PubMed Web of Science ®Google Scholar
• Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton). 2010;15:165–170
   PubMed Web of Science ®Google Scholar
• Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (promiss) trial – A randomized controlled study. Am Heart J. 2008;155:499.e491–499.e498
   Web of Science ®Google Scholar
• Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37:394–396
   PubMedGoogle Scholar
• Wang ZCH, Pan YD. Effect of atorvastatin on renal function in patients given contrast medium after interventional procedures. Med J Chin People's Armed Police Forces. 2009;20:919–922
   Google Scholar
• Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105:288–292
   PubMed Web of Science ®Google Scholar
• Ozhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61:711–714
   PubMedGoogle Scholar
• de Oliveira MSA-MK, Ribamar-Costa J Jr, Abizaid A, et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users. Rev Bras Cardiol Invasiva. 2012;20:303–308
   Google Scholar
• Acikel S, Muderrisoglu H, Yildirir A, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010;21:750–757
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–872
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118
   PubMed Web of Science ®Google Scholar
• Chade AR, Zhu XY, Grande JP, Krier JD, Lerman A, Lerman LO. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008;26:1651–1660
   PubMedGoogle Scholar
• Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114:562–570
   PubMed Web of Science ®Google Scholar
• Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc. 2004;79:211–219
   PubMed Web of Science ®Google Scholar
• Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Am J Nephrol. 2011;33:344–351
   PubMed Web of Science ®Google Scholar